SCHEMBL6722332

SCHEMBL6722332

CC(=O)OC(C)(Cc1nc2c(N)nc3ccccc3c2[nH]1)CC(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 1/20 0.36
TLR7 Q9NYK1 12/20 0.36
TLR8 Q9NR97 8/20 0.36
NUDT1 P36639 2/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
HRH2 P25021 1/20 0.35
ADRA1D P25100 1/20 0.35
HTR2A P28223 1/20 0.35
ADORA2A P29274 1/20 0.35
ADRA1A P35348 1/20 0.35
HTR2B P41595 1/20 0.35
PDE4D Q08499 1/20 0.35
KCNH2 Q12809 1/20 0.35
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
GAA P10253 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
AAK1 Q2M2I8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7082511 0.82 TLR7 (0.37) TLR7TLR8NUDT1LMNAPOLB
SCHEMBL6724720 0.82 AAK1 (0.37) MEN1NPC1GAARAB9AKMT2A
Water SCHEMBL6726680 0.81 TLR7 (0.36) TLR7TLR8NUDT1LMNAPOLB
SCHEMBL20761545 0.72 NLRP3 (0.51) NLRP3TLR7TLR8LMNAMEN1
SCHEMBL20760997 0.72 ELANE (0.49) NLRP3TLR7TLR8NPC1RAB9A
Isobutanol SCHEMBL10444099 0.71 KMT2A (0.45) TLR7TLR8NUDT1LMNAPOLB
SCHEMBL8600371 0.71 TNKS2 (0.53) TLR7TLR8ADORA2A
SCHEMBL18268482 0.70 TLR7 (0.41) TLR7TLR8NUDT1LMNAPOLB
SCHEMBL20762268 0.70 NLRP3 (0.67) NLRP3TLR7TLR8LMNAMEN1
SCHEMBL20968264 0.69 TP53 (0.42) TLR7ELANEHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030119861-A1 Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines 3M INNOVATIVE PROPERTIES COMPANY 2003-06-26 US claimed
US-20020115861-A1 Process for preparing 1-substituted, 2-substituted 1H-imidazo [4, 5-c] quinoline-4-amines 3M INNOVATIVE PROPERTIES COMPANY 2002-08-22 US claimed
EP-0582581-B1 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES MINNESOTA MINING & MFG (US) 1999-05-06 EP claimed
US-5605899-A VIRICIDES, BIOSYNTHESIS OF INTERFERONS, ANTITUMOR AGENTS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-02-25 US claimed
WO-1992015582-A1 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1992-09-17 WO claimed
US-6790961-B2 REACTING A 3-AMINO-4-(SUBSTITUTED)AMINO-2-CHLOROQUINOLINE WITH AN ALKYLCARBONYL CHLORIDE TO FORM THE 2-ALKYLCARBOXAMIDE INTERMEDIATE 3M INNOVATIVE PROPERTIES COMPANY 2004-09-14 US disclosed
US-20040122231-A1 Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines 3M INNOVATIVE PROPERTIES COMPANY 2004-06-24 US disclosed
US-6686472-B2 Process for preparing 1-substituted, 2-substituted 1-H-imidazo(4,5-c)quinolin-4-amines 3M INNOVATIVE PROPERTIES COMPANY 2004-02-03 US disclosed
US-20030212270-A1 Process for preparing 1-Substituted, 2-Substituted 1-H-Imidazo(4,5-c)quinolin-4-Amines 3M INNOVATIVE PROPERTIES COMPANY 2003-11-13 US disclosed
US-6608201-B2 Amidation of a 2-halo-3,4-diaminoquinoline with an acid chloride; dehalogenation, amination with ammonia; cyclization 3M INNOVATIVE PROPERTIES COMPANY 2003-08-19 US disclosed
US-20030119861-A1 Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines 3M INNOVATIVE PROPERTIES COMPANY 2003-06-26 US disclosed
EP-0872478-B1 Intermediates for the preparation of 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines MINNESOTA MINING & MFG (US) 2002-12-18 EP disclosed
US-20020115861-A1 Process for preparing 1-substituted, 2-substituted 1H-imidazo [4, 5-c] quinoline-4-amines 3M INNOVATIVE PROPERTIES COMPANY 2002-08-22 US disclosed
US-6348462-B1 VIRICIDES 3M INNOVATIVE PROPERTIES COMPANY 2002-02-19 US disclosed
US-5977366-A 1-substituted, 2-substituted 1H-imidazo[4,5-c] quinolin-4-amines 3M INNOVATIVE PROPERTIES COMPANY (US) 1999-11-02 US disclosed
EP-0582581-B1 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES MINNESOTA MINING & MFG (US) 1999-05-06 EP disclosed
EP-0872478-A2 Intermediates for the preparation of 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1998-10-21 EP disclosed
US-5605899-A VIRICIDES, BIOSYNTHESIS OF INTERFERONS, ANTITUMOR AGENTS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-02-25 US disclosed
US-5389640-A Viricides, antitumor agents MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1995-02-14 US disclosed
WO-1992015582-A1 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1992-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212270-A1 Process for preparing 1-Substituted, 2-Substituted 1-H-Imidazo(4,5-c)quinolin-4-Amines IFNAR1, IRF3, IFNG NLRP3 3443/4885TLR7 101/4885TLR8 382/4885
US-20020115861-A1 Process for preparing 1-substituted, 2-substituted 1H-imidazo [4, 5-c] quinoline-4-amines IFNAR1, IFNG, IRF3 NLRP3 2540/4885TLR7 54/4885TLR8 335/4885
US-20040122231-A1 Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines UGT1A4, QARS1, HTR4 NLRP3 3092/4885TLR7 1287/4885TLR8 1825/4885
US-20030119861-A1 Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines IRF3, IFNAR1, IFNG NLRP3 3324/4885TLR7 105/4885TLR8 336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.